Given TRPM2’s role in both atherosclerosis and GLP-1-induced insulin secretion as discussed above [21], further research on GLP-1/TRPM2 interactions could enable further pharmacological targeting of macrophage-related inflammation in diabetes and ASCVD. The gene discussed is GLP1R; the disease is atherosclerosis.